CHA
ITCI

Cooper/Haims Advisors’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Cooper/Haims Advisors’s Portfolio ITCI Stock Details ITCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-61,116
Closed -$3.2M – 89
2021
Q4 		$3.2M Hold
61,116
– – 1.97% 10
2021
Q3 		$2.28M Hold
61,116
– – 1.37% 14
2021
Q2 		$2.5M Buy
+61,116
New +$2.26M 1.64% 11

Other funds holding ITCI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Cooper/Haims Advisors's ITCI Position: Q1 2022 in Review

Cooper/Haims Advisors sold out of Intra-Cellular Therapies Inc. (ITCI) in Q1 2022, closing a stake of 61,116 shares — an estimated $3.2M sold.

Cooper/Haims Advisors first reported a position in ITCI in Q2 2021 and held it in 3 quarters. The position peaked at $3.2M in Q4 2021. 241 funds tracked by Wall St. Rank hold ITCI as of Q1 2022.

  • Cooper/Haims Advisors reported no remaining Intra-Cellular Therapies Inc. position as of Q1 2022 after selling out during the quarter.
  • Cooper/Haims Advisors sold 61,116 Intra-Cellular Therapies Inc. shares in Q1 2022, an estimated $3.2M.
  • Cooper/Haims Advisors first reported a position in Intra-Cellular Therapies Inc. in Q2 2021 and held it in 3 quarters.
  • Cooper/Haims Advisors's Intra-Cellular Therapies Inc. position peaked at $3.2M in Q4 2021.
  • 241 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q1 2022.

Based on Cooper/Haims Advisors's 13F filing for Q1 2022, filed 9 May 2022.